Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2005

View Archived Issues

Good results obtained with a meningococcal/pneumococcal vaccine in infants

Extended use of the contraceptive NuvaRing reported safe and effective

New data on the benefits of lasofoxifene in vaginal atrophy

Update on the effects of lanthanum carbonate in dialysis patients

Blocking cathepsins alleviates experimental colitis / News in Context

Dermatological application for NeoPharm's new compound K6PC-5

New approaches to influenza vaccine

Nabi Biopharmaceuticals begins early clinical development of S. epidermidis vaccine

SCLOR Pharma evaluates bioavailability of CDT-raloxifene

Ziopharm initiates early clinical development of ZIO-101

Acologix expands AC-100 phase II development for periodontal bone loss

IMI to change name to PreMD

Chromos to acquire Targeted Molecules

Alfimeprase phase III program for CO indication poised for initiation

Patient enrollment continues in world's largest drug-eluting stent registry

Preliminary efficacy data does not support further clinical development of palosuran

Philinopside A exerts antiangiogenic and cytotoxic effects in vitro and in vivo

Cardioprotective properties of ARD-353 described in a preclinical model

Synthetic derivative of rocaglaol effective in preclinical models of neurodegenerative diseases

Focalin XR approved for ADHD

Cylene completes financing to advance CX-3543 into the clinic

New Invirase 500 mg formulation approved in Europe

Hylenex NDA accepted for review

CytoGenix licenses DNA plasmid from NIH

Merrem approved for complicated skin and skin structure infections

First phase I study of OT-551 for cataracts meets all safety and comfort endpoints

Antisense technology provides therapeutic target in lymphoproliferative disorders

Recent patents report new treatments for psychotic disorders

Novel antiinflammatory agents claimed in patent literature

Epithelial sodium channel blockers discovered at Parion

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....